Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions

Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions

Glioblastoma (GBM) is among the most fatal and recurring malignant solid tumors. It arises from the GBM stem cell population. Conventional neurosurgical resection, temozolomide (TMZ)-dependent chemotherapy and radiotherapy have rendered the prognosis of patients unsatisfactory. Radiotherapy and chem...

Full description

Bibliographic Details
Main Authors: Mingming Wang, Xiaojie Wang, Xiaoyan Jin, Jingjing Zhou, Yufu Zhang, Yiyuan Yang, Yusi Liu, Jing Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
temozolomide
cell-based immunotherapies
cell-free immunotherapies
treatment strategy
glioblastoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1175118/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1175118/full

Similar Items